During the call, the Company will also provide a clinical data update from the AFM24-102 trial.
The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the 'Webcasts' section on the 'Investors' page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://register.vevent.com/register/BIb2258d6c5f5a474cad74869a7b7b1bb5, and you will be provided with dial-in details and a pin number.
About
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE) molecules, which use patients' immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE. Headquartered in Mannheim,
Contact:
Alexander Fudukidis
Email: a.fudukidis@affimed.com
Tel: +1 (917) 436-8102
(C) 2023 Electronic News Publishing, source